#Sweden #Stockholm #Moberg Pharma #MOB-015 #Karo Healthcare

Karo Healthcare Secures Exclusive Licensing Agreement with Moberg Pharma for MOB-015 in Europe

Introduction
In an exciting development within the pharmaceutical sector, Karo Healthcare AB has announced it has entered into an exclusive licensing agreement with Moberg Pharma AB. This partnership pertains to the commercialization of MOB-015, a new topical treatment designed for onychomycosis (nail fungus), across 19 key European markets. This strategic move is poised to significantly enhance Karo's footprint in the foot health category, which has become one of its core business focuses.

Details of the Agreement
The licensing agreement encompasses a substantial population of over 500 million people, which includes major markets in the European Union as well as the United Kingdom, collectively known as the 'Big 5.' Notably, several of these countries already have existing approvals for MOB-015, although the product has yet to be launched there. Karo will take charge of all marketing, distribution, and sales processes in these markets, leveraging its established brand reputation and expertise.

Karo Healthcare's CEO, Christoffer Lorenzen, expressed enthusiasm about the collaboration, emphasizing the strong alignment of Moberg Pharma's innovative products with Karo's existing portfolio. "We are intensifying our efforts in the foot health sector, and with MOB-015, we are poised to offer consumers a highly effective treatment option under the globally recognized Lamisil® brand."

Strengthening the Foot Health Portfolio
MOB-015 is touted as the next generation of terbinafine therapy, overcoming previous challenges faced by topical treatments in delivering sufficient amounts of active ingredients to the nail. Registration studies have shown that this new formulation achieves a mycological cure in 76% of patients, a breakthrough that places it on par with traditional oral treatments.

Lorenzen continued, "The successful launch of MOB-015 under the reputable Lamisil® brand is expected to strengthen our leadership position in the European antifungal market. We are committed to contributing to consumer health and wellness through innovative solutions."

Moberg Pharma's Positioning
On the flip side, Moberg Pharma's CEO, Anna Ljung, shared her excitement regarding the licensing partnership. She noted, "Karo has a strong presence throughout Europe, and together we can leverage the well-established Lamisil® brand to ensure that MOB-015 becomes a market leader, reaching consumers beyond our existing markets in Sweden and Norway."

Conclusion
This licensing agreement marks a significant milestone for both Karo Healthcare and Moberg Pharma, as they venture together into a major European expansion for MOB-015. With a combined focus on scientific innovation and strategic market execution, this partnership holds promise not only for their respective companies but also for the future of consumer health products in Europe.

Karo Healthcare, headquartered in Stockholm, operates in over 90 countries, offering a wide range of well-known brands such as Lamisil®, E45®, and Pevaryl®. Similarly, Moberg Pharma, also based in Stockholm, focuses on commercializing proprietary drug delivery innovations backed by solid clinical evidence. Together, they aim to respond effectively to the pressing needs of consumers for effective antifungal treatments in the European region.

For Further Information
For more details regarding this agreement or any inquiries, please reach out to the leadership teams at Karo Healthcare and Moberg Pharma, who are available for comment and additional clarification regarding the implications of this collaboration.